Konstantinos Angelis - Dept Biostat, GlaxoSmithKline

基本信息

浏览量：1

职业迁徙

个人简介

http://abacus.gene.ucl.ac.uk/kostas/ https://www.linkedin.com/profile/view?id=248685494&trk=nav_responsive_tab_profile

研究兴趣

论文共 33 篇作者统计合作学者相似作者

按年份排序按引用量排序主题筛选期刊级别筛选合作者筛选合作机构筛选

Pharmacokinetic and Pharmacokinetic/pharmacodynamic Characterization of the Dolutegravir/rilpivirine Two‐drug Regimen in SWORD‐1/‐2 Phase 3 Studies

Rashmi Mehta,Chakradhar V. Lagishetty,Konstantinos Angelis,Alicia Aylott,Lesley Kahl,Libby Blair,Jessica Matthews,Brian Wynne,Herta Crauwels,Mark Underwood,Kimberly K. Adkison

British Journal of Clinical Pharmacology（2023）

引用0浏览0WOS引用

Sustained Virologic Suppression with Dolutegravir/Lamivudine in a Test-and-Treat Setting Through 48 Weeks

Charlotte-Paige Rolle,Mezgebe Berhe,Tulika Singh,Roberto Ortiz,Anson Wurapa,Moti Ramgopal,Dushyantha T. Jayaweera,Peter A. Leone,Jessica E. Matthews,Michael Cupo,Mark R. Underwood,Konstantinos Angelis,Brian R. Wynne,Deanna Merrill,Christopher Nguyen,Jean van Wyk,Andrew R. Zolopa

OPEN FORUM INFECTIOUS DISEASESno. 3 (2023)

引用6浏览0WOS引用

Patient-reported symptom outcomes following DTG/3TC use in a test-and-treat setting: results from the STAT Study

A. Oglesby,J. Matthews,K. Angelis,P. Leone, M. Cupo,B. Wynne,D. Merrill,C. Nguyen,J. Van Wyk,A. Zolopa

JOURNAL OF THE INTERNATIONAL AIDS SOCIETY（2022）

引用0浏览0引用

Feasibility, Efficacy, And Safety Of Using Dolutegravir/Lamivudine (Dtg/3tc) As A First-Line Regimen In A Test-And-Treat Setting For Newly Diagnosed People Living With Hiv (Plwh): The Stat Study

Charlotte-Paige Rolle,Mezgebe Berhe,Tulika Singh,Roberto Ortiz,Anson Wurapa,Moti Ramgopal,Peter A. Leone,Jessica E. Matthews,Marybeth Dalessandro,Mark R. Underwood,Konstantinos Angelis,Brian R. Wynne,Deanna Merrill,Christopher Nguyen,Jean Van Wyk,Kathrin M. Dymek

INFECTION（2021）

引用4浏览0引用

Dolutegravir/lamivudine As a First-Line Regimen in a Test-and-treat Setting for Newly Diagnosed People Living with HIV

AIDS（2021）

引用30浏览0WOS引用

Feasibility, efficacy, and safety of using dolutegravir/lamivudine (DTG/3TC) as a first-line regimen in a test-and-treat setting for newly diagnosed PLWH: the STAT study

C. Rolle,M. Berhe, T. Singh,R. Ortiz, A. Wurapa,M. Ramgopal,P. Leone,J. Matthews,M. Dalessandro,M. Underwood,K. Angelis,B. Wynne,D. Merrill,C. Nguyen,J. van Wyk

JOURNAL OF THE INTERNATIONAL AIDS SOCIETY（2020）

引用4浏览0引用

Dolutegravir-based Antiretroviral Therapy for Patients Coinfected With Tuberculosis and Human Immunodeficiency Virus: A Multicenter, Noncomparative, Open-label, Randomized Trial

Kelly E. Dooley,Richard Kaplan,Noluthando Mwelase,Beatriz Grinsztejn,Eduardo Ticona,Marcus Lacerda,Omar Sued,Elena Belonosova,Mounir Ait-Khaled,Konstantinos Angelis,Dannae Brown,Rajendra Singh,Christine L. Talarico,Allan R. Tenorio,Michael R. Keegan,Michael Aboud

CLINICAL INFECTIOUS DISEASES（2020）

引用66浏览0WOS引用

SWORD 1&2: maintenance or improvement in renal function in PLWH through 148 weeks after switch to the dolutegravir plus rilpivirine 2-drug regimen

J. M. Llibre,E. Voronin,R. Rubio,P-M Girard, F. Bredeek,J. van Wyk,L. Kahl,B. Jones,L. Curtis,B. Wynne,M. Nascimento,J. Koteff,M. Gartland,K. Angelis,K. Vandermeulen,K. Y. Smith

HIV MEDICINE（2019）

引用0浏览0引用

Population pharmacokinetic analysis of dolutegravir in HIV/TB co-infected people with and without rifampicin

R. Singh,H. Chandasana,K. E. Dooley,R. Kaplan,N. Mwelase,B. Grinsztejn,E. Ticona,M. Lacerda,O. Sued,E. Belonosova,M. Ait-Khaled,K. Angelis,D. Brown,C. L. Talarico,A. R. Tenorio, M. R. Keegan,M. Aboud

HIV MEDICINE（2019）

引用0浏览0引用

加载更多

作者统计

合作学者

合作机构

D-Core

合作者
学生
导师

暂无相似学者，你可以通过学者研究领域进行搜索筛选

数据免责声明

页面数据均来自互联网公开来源、合作出版商和通过AI技术自动分析结果，我们不对页面数据的有效性、准确性、正确性、可靠性、完整性和及时性做出任何承诺和保证。若有疑问，可以通过电子邮件方式联系我们：report@aminer.cn